| Oct 24 |
UBS launches SMID cap biotechs with cancer, autoimmunity in focus
|
| Oct 14 |
Kura downgraded to hold by Stifel, prefers rival Syndax
|
| Oct 9 |
Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
|
| Oct 4 |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
| Sep 23 |
Syndax Pharmaceuticals: One Down And One To Go
|
| Sep 20 |
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
|
| Sep 18 |
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
|
| Sep 13 |
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
|
| Sep 5 |
Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
|
| Aug 15 |
FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
|
